LONA.US LeonaBio, Inc.

Healthcare Pharmaceuticals USA Stocks
3.47 USD
Close of Nov 15, 2026
2.21 14.21
Market cap
USD 32.7M
P/E
-
P/B
0.97x
ROE
-309.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is LONA.US undervalued?

Graham number

The Graham number of LeonaBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LeonaBio, Inc. fundamental analysis

No fundamental analysis for LeonaBio, Inc. yet.

LeonaBio, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LeonaBio, Inc.

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for th…

Full company profile